FDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MiniMed (Nasdaq: MMED) received FDA clearance for MiniMed Fit, its first tubeless insulin pump, for people with diabetes ages 7 and older.
The clearance covers Type 1 and Type 2 diabetes. The pump offers up to seven days of wear and a 300-unit insulin capacity, with app control and SmartGuard automated insulin delivery. Seven-day wear requires a total daily insulin dose of less than 42 units; daily dosage may affect replacement frequency.
MiniMed expects a phased U.S. rollout in spring 2027, following an early customer experience phase expected in its fourth quarter of fiscal 2027. Access will be through pharmacies. The company has been building manufacturing capacity and commercial infrastructure and plans further capacity expansion as commercialization progresses. It also plans integration with its next-generation fully closed-loop technology, which remains investigational.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointFDA clearance adds MiniMed's first tubeless pump for Type 1 and Type 2 diabetes, ages 7 and older.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Phased U.S. rollout is expected in spring 2027, following an early experience phase expected in fiscal Q4 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Manufacturing capacity and commercial infrastructure have been under development; MiniMed plans further manufacturing expansion as commercialization progresses.
- Minor point. Forward-looking: it has not happened yet and may not happen.Future integration with MiniMed's next-generation fully closed-loop technology is planned; that technology remains investigational.
Negative
- Minor pointSeven-day wear requires less than 42 units of total daily insulin; dosage may affect replacement frequency.
Key Figures
- Pump wear
- Up to seven days
- MiniMed Fit
- Insulin capacity
- 300 units
- MiniMed Fit pump
- Instinct sensor wear
- Up to 15 days
- Abbott sensor option at commercial launch
- Time in Range
- Up to 80%
- Real-world SmartGuard users with recommended settings
- Overnight Time in Range
- 91%
- Real-world SmartGuard users with recommended settings
- Phased U.S. rollout
- Expected to begin in spring 2027
- MiniMed Fit launch
- Early customer experience phase
- Expected to begin in fiscal year 2027 fourth quarter
- Ahead of the phased U.S. rollout
- Cleared age eligibility
- Ages 7 and older
- People with Type 1 and Type 2 diabetes
Previous Fda approval Reports
-
Earlier clearance established SmartGuard and 300-unit pump features; this clearance adds a tubeless design.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
automated insulin delivery medical
closed-loop technology technical
real-world evidence medical
fda clearance regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The only tubeless pump with no charging or cartridge changes for up to seven days, combined with a 300-unit insulin capacity and advanced insulin automation
MiniMed Fit™ marks a significant expansion of the company's insulin delivery portfolio, bringing its advanced automated insulin delivery technology to a tubeless design for the first time. With up to twice the wear time of other tubeless options* and
"People with diabetes shouldn't have to choose between the freedom of tubeless wear and the health outcomes they deserve," said Que Dallara, chief executive officer of MiniMed. "MiniMed Fit™ brings the technology people trust from MiniMed into a tubeless design that fits their lives. Clearing FDA ahead of schedule is more proof we're executing our strategy. It puts MiniMed Fit in
Everything a tubeless pump should be
MiniMed Fit™ is designed to automate more of the work of diabetes management and reduce interruptions in daily routines. It combines a discreet, waterproof tubeless pump with app control on compatible iOS and Android devices and at commercial launch will offer the choice of two all-in-one sensors: Simplera Sync™ with up to seven days of wear and Instinct™, made by Abbott, with up to 15 days of wear.
- Fewer changes. More freedom. With up to seven days of wear and 300-unit insulin capacity, MiniMed Fit™ offers up to twice the wear time and more insulin than other tubeless insulin pump options, meaning fewer pump changes and more time to focus on what matters. *†‡
- Automation every five minutes. Powered by SmartGuard™ technology, the system automatically adjusts insulin delivery and can deliver correction doses every five minutes.§
- Easier mealtimes. With Meal Detection™ technology, the system can deliver additional insulin when a meal dose is sometimes missed or underestimated. §‖
- More time in range, day and night. Real-world users of SmartGuard™ technology have achieved up to
80% Time in Range and91% overnight Time in Range with recommended settings, helping people spend more time in their target glucose range. ¶ #**1,2 - Flexible wear locations and insulin compatibility. Wear locations are back of arm, lower back, upper buttocks, abdomen, and thigh. Compatible insulins are Humalog, NovoLog, and Admelog.
- Easier access through the pharmacy. MiniMed Fit™ will be available through the pharmacy channel, offering a convenient way for people to access.
- Built for what's next. MiniMed Fit™ is designed for future innovation, including the planned integration with MiniMed's next-generation fully closed-loop technology (investigational).
The MiniMed Fit™ launch is expected to begin with a phased rollout in the
In preparation for launch, MiniMed has been building manufacturing capacity and commercial infrastructure alongside the regulatory process. The company plans to significantly expand manufacturing capacity as commercialization progresses to support growing demand and capitalize on a new growth opportunity in tubeless insulin pumps.
MiniMed Fit™ is cleared for people with Type 1 and Type 2 diabetes ages 7 and older. People interested in learning more about MiniMed Fit™ availability can request to receive updates at minimed.com/fit.
About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.
Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Footnotes & References
*Tandem Mobi can be worn up to 7 days with a required cartridge change at 3 days. Omnipod can be worn up to 3 days. Mint has 3-day wear, plus a 12-hour grace period for insulin delivery. See user guides for more details.
† Omnipod, Mint, and Mobi tubeless devices hold 200 units. See product IFUs for details.
‡ 7-day wear achievable with less than 42 units of total daily dose. Total daily dose may impact frequency of changes.
§ Refers to SmartGuard™ feature. Individual results may vary.
‖ Taking a bolus 15–20 minutes before a meal helps to keep blood sugar levels under control after eating.
¶ Due to inherent real-world data limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.
# Real-world evidence. N=101,629.
** Overnight period: 12:00 AM- 6:00 AM. Number of users with ≥10 days of sensor glucose data; Optimal settings are glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours and used >
∞ Pump is waterproof up to 8 feet (2.4 meters) for 1 hour and 45 minutes. If you choose to stay connected while in water, CGM readings may not be transmitted to the pump.
1. Choudhary P, et al. Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence. Diabetes Technol Ther. 2024;26 (Suppl. 3):S32-S37.15
2. McVean JJF, Niu F, Liu M, et al. Automated insulin delivery with the MiniMed™ 780G system reduces burden by improving sleep and glycaemic control overnight. Diabetes Obes Metab. 2026;28(3):2456-2460. doi:10.1111/dom.70380
View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-clears-minimed-fit--worlds-first-and-only-tubeless-insulin-pump-with-up-to-seven-day-wear-and-zero-interruptions-302940510.html
SOURCE MiniMed
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.